Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $29 and keeps an Overweight rating on the shares. While management continues to execute on bexdeg’s chronic lymphocytic leukemia trials with some modest updates expected at EHA, the firm believes bexdeg’s opportunity in immunology and inflammation remains underappreciated. Wells sees data from ONC’s BTKdeg BGB-16673 for chronic spontaneous urticaria in the first half of 2026 as a potential upside catalyst.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $34 from $35 at Stifel
- Nurix Therapeutics: Buy Rating Backed by Advancing Bexobrutideg Program, Sanofi STAT6 Milestones, and Solid Cash Runway
- Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL
- Midday Fly By: Delta reports Q1 beat, Bed Bath & Beyond to buy F9 Brands
- Nurix Therapeutics reports Q1 EPS (79c), consensus (76c)